Acute myocardial infarction (AMI) is one of the most serious conditions encountered in the emergency room (ER), with outcomes that are highly affected by the time elapsed since symptoms onset. The diagnosis of AMI is currently based on clinical judgment, electrocardiogram (ECG), biomarkers, and in cases of uncertainty, imaging modalities. Currently, high-sensitivity troponin (hs-cTnI) is the recommended biomarker for early diagnosis of AMI [1]. Among other putative biomarkers, heart-type fatty acid binding protein (H-FABP) has recently gained focus as a diagnostic and prognostic biomarker [2].
